מתוך אתר medicontext.co.il WESTPORT, CT (Reuters Health) – Antenatal maternal use of magnesium sulfate, but not ritodrine, is associated with reduced brain-blood flow perfusion in preterm infants, according to a report published in the July issue of Critical Care Medicine.
Dr. Tiina Rantonen, from the University of Turku in Finland, and colleagues assessed the impact of maternal tocolytic use on the cerebral blood flow parameters of 55 preterm infants who were less than 33 weeks' gestational age. Nineteen of the infants' mothers received magnesium sulfate during pregnancy, 17 received ritodrine, and 19 did not receive a tocolytic agent.
No consistent effects on neonatal cerebral or systemic hemodynamics were noted with maternal ritodrine use, the authors state.
While maternal magnesium sulfate use did not affect neonatal cerebral blood flow velocity or resistance, it was linked to reduced perfusion pressure and blood flow in the anterior cerebral and internal carotid arteries during the first day of life. In addition, magnesium sulfate-exposed infants had lower systolic blood pressures and pulse pressures during the whole study period than did unexposed infants.
"Our study suggests that maternal magnesium sulfate decreases the cerebral perfusion pressure and blood flow, and this likely protects the germinal matrix against the development of circulatory stress in the early postnatal period," the researchers postulate. However, further studies are needed "to investigate whether magnesium sulfate exposure is a risk for ischemic events," they add.
Crit Care Med 2001;29:1460-1465.